Issue 1 JANUARY 2019

The Veeda Newsletter


What the GSK-Pfizer merger means for their Indian units

Investors are excited about GlaxoSmithKline Plc’s (GSK) plan to split the firm into two entities—pharmaceuticals and consumer healthcare.
Read more:

Fuji Pharma Acquires 4.2% Stake in Biosimilar Developer Alvotech

The acquisition comes less than 2 months after the companies announced that they had entered into a partnership agreement for the commercialization of Alvotech’s entire pipeline of biosimilars in Japan
Read more :

Taiwan’s Mycenax looking for acquisitions; updates on biosimilar

Taiwan's major biotech manufacturing service provider Mycenax Biotech plans to buy some new drug testing platforms and a small cell strain supplier primarily in the US and Japan in 2019.
Read more :

Healthcare sector may see further consolidation in 2019

Healthcare sector may see further consolidation in 2019 with tightening of regulatory environment set to make it difficult for small players to stay afloat in a highly competitive market.
Read more at:

Indian drugmakers hit record year for M&A and deal values

Activity in the pharma sector is rife in India, with mergers and acquisition deal values doubling given
Read more :
Contact Us